In the manufacture of sterile veterinary erythromycin ophthalmic ointment, the API is micronized in a fluidized-bed opposed-jet mill until the particle size distribution reaches a D90 of ≤15 µm and a D50 of 3–5 µm; any oversize fraction above 25 µm is rejected because coarse particles raise the risk of corneal abrasion and cause content non-uniformity when the batch is blended at low shear. The micronized erythromycin base is packaged in double polyethylene liners under ≤30% relative humidity and held at 20–25°C before incorporation into an anhydrous ointment base composed of white petrolatum, light mineral oil, and lanolin alcohols. The base is heated to 70°C in a jacketed vacuum planetary mixer and sterilized at 160–170°C for not less than 120 min; after cooling to 45–50°C under sterile nitrogen, the active is added aseptically and dispersed with a sweep anchor at 15–25 rpm until assay uniformity across ten sampling ports shows relative standard deviation ≤3.0%. The target potency is 5 mg erythromycin activity per gram, equivalent to 0.5% w/w. Processing above 55°C is avoided because erythromycin degradation in the molten base accelerates sharply, while processing below 40°C increases ointment viscosity beyond the 2,500 cP range required by the filling nozzle. The finished ointment is tested for sterility by USP <71> membrane filtration after dispersion in isopropyl myristate, assay and related substances by the high-performance liquid chromatographic procedures of Ph Eur monograph 0179, metal particles by USP <751>, and general ophthalmic preparation attributes by USP <771>; the antimicrobial effectiveness test of USP <51> applies when a preservative is included in the formulation, though many single-use ophthalmic antibiotic ointments rely on the antibiotic activity and omits the preservative. Moisture content is limited to ≤0.5% w/w by USP <921> Method Ia because free water hydrolyzes the macrolide lactone ring. The ointment is filled into 3.5 g and 7 g aluminum or LDPE tubes under ISO 14644-1:2015 class 5 conditions and sealed with a heated jaw head; terminal sterilization is not used because erythromycin shows unacceptable potency loss in petrolatum above 60°C. Residual peroxide in the white petrolatum is limited to ≤100 mEq/kg before manufacture because peroxides oxidize erythromycin to erythromycin N-oxide during storage at 30°C/65% RH. Finished product types are 3.5 g and 7 g tubes of veterinary ophthalmic ointment for cattle, sheep, cats, and dogs.

What Constrains Filter Throughput When Erythromycin Lactobionate Is Compounded at 200 mg/mL?

Erythromycin lactobionate is selected for injectable formulations because its aqueous solubility exceeds 200 mg/mL at 25°C, whereas erythromycin base solubility remains below 2 mg/mL and cannot support a 200 mg/mL parenteral product without excessive organic co-solvent. The formulation target is 50 mg/mL or 200 mg/mL erythromycin activity, with an API overage of 102–105% of label claim at release to account for assay variation and adsorption losses on sterilizing filters. The vehicle contains 0.9% w/v benzyl alcohol as antimicrobial preservative and citric acid/sodium citrate buffer to maintain pH 6.5–7.0; below pH 5.5, erythromycin A converts to anhydroerythromycin and other acid-catalyzed degradation products, with total impurities increasing above 0.5% after 30 days at 25°C. The solution is compounded in a closed 316L stainless-steel vessel with a bottom-entry magnetic impeller at 180–250 rpm under a nitrogen overlay of 0.2–0.5 bar; dissolved oxygen is held below 0.5 mg/L and the nitrogen moisture below 10 ppm to limit oxidative formation of erythromycin N-oxide. The liquid is passed through a 5 µm stainless-steel guard filter, a 0.45 µm PVDF bioburden reduction cartridge at a constant flux of 200 L/m²/h, and a 0.22 µm PES sterilizing filter; at 200 mg/mL, transmembrane pressure on a 10-inch cartridge rises from 0.3 bar to 0.8 bar after 200 L/m² of batch volume, a fouling pattern that is controlled by prefilter selection and by maintaining the temperature at 20–30°C to avoid solubility fluctuations. The filtered solution is filled under ISO 14644-1:2015 class 5 conditions in a restricted access barrier system into depyrogenated Type I glass vials that were washed and subjected to dry-heat depyrogenation at 250°C for 45 min; the vials are purged with nitrogen and closed with bromobutyl rubber stoppers. Terminal autoclaving is avoided because erythromycin lactobionate shows visible color development and a 3–5% potency loss after exposure to 121°C for 15 min; therefore aseptic filtration is the only acceptable sterilization route for this formulation. Release testing includes bacterial endotoxins by USP <85> with a limit of 0.5 EU/mg, particulate matter by USP <788>, osmolality by USP <785>, fill volume by USP <1>, residual solvents by VICH GL18, and related substances by Ph Eur 2.2.29. Dilution with calcium-containing intravenous fluids is avoided because calcium ions can reduce the effective solubility of the macrolide and cause microprecipitation in administration lines. Benzyl alcohol content also restricts use in neonatal calves according to the toxicological assessment in the target market authorization. The terminal products are 100 mL and 250 mL Type I glass vials containing 50 mg/mL or 200 mg/mL erythromycin activity for intramuscular or slow intravenous administration in cattle and swine.

Film-Coated Tablet Compression and the 12 kN Lower Bound for Disintegration

Film-coated erythromycin tablets for canine and feline oral administration are formulated with erythromycin ethylsuccinate because the ester salt reduces solution-state acid degradation and masks the intense bitterness of erythromycin base. The granulation is manufactured in a high-shear mixer with an impeller speed of 150–250 rpm and a chopper speed of 1,500–2,500 rpm, using purified water or an ethanol-water mixture at 50:50 as the granulating fluid; the dry blend contains ethylsuccinate equivalent to 100 mg or 200 mg erythromycin activity per tablet, lactose monohydrate, pregelatinized starch at 5–10% w/w, croscarmellose sodium at 2–4% w/w, and colloidal silicon dioxide at 0.25–0.5% w/w. The wet mass is dried in a fluid-bed dryer at 45–55°C to a moisture content of 1.5–2.5% w/w, then milled through a 1.0 mm screen. Magnesium stearate is added at 0.5% w/w and blended for 3–5 min in a bin blender at 15 rpm; a longer lubrication time reduces tablet hardness and increases dissolution time because excessive hydrophobic coating on granules retards water penetration. Compression is performed on a 27-station rotary tablet press with a compression force of 12–18 kN and a target hardness of 80–120 N. Tablets compressed below 12 kN show capping during film coating and disintegration variability above 10% RSD; tablets compressed above 18 kN exhibit prolonged disintegration and lamination risks. The core weight is 500 mg with a thickness of 4.8–5.2 mm. Film coating is applied in a side-vented pan coater at 3–4% weight gain using hydroxypropyl methylcellulose, polyethylene glycol 400, titanium dioxide, and purified water; inlet air temperature is 60–70°C, pan speed 6–12 rpm, and spray rate 8–12 g/min per kg of tablet charge. Dissolution is tested per USP <711> apparatus II at 50 rpm in pH 6.8 phosphate buffer, with Q=75% at 45 min; disintegration is tested per USP <701>; assay follows Ph Eur monograph 0179 or the relevant USP erythromycin preparation monograph; organic volatile impurities are controlled by USP <467>. The film coat provides a moisture barrier, but storage above 65% relative humidity for 21 days increases hydrolysis-related impurities by 0.3–0.6 percentage points; therefore the tablets are packaged in aluminum/aluminum blister strips and stored below 25°C and 60% relative humidity. The terminal dosage forms are 100 mg and 200 mg film-coated tablets for dogs and cats; the same granulation may be filled into hard gelatin capsules for species that require divided dosing.

Because feed-mill incorporation requires carrier bonding rather than aqueous dissolution, erythromycin thiocyanate is first blended with calcium carbonate and corn cob granules to form a 10% w/w premix before further dilution in a horizontal ribbon mixer. Complete poultry feed is targeted at 92.5–185 g erythromycin activity per metric ton, depending on the veterinary prescription and the respiratory disease control protocol; the 10% w/w premix is metered at 0.925–1.85 kg per tonne to deliver that range. The mixer is operated at 60–80 rpm with a fill volume of 60–70% of geometric capacity; the active is first mixed with an equal mass of calcium carbonate for 5 min, then diluted in three geometric steps to achieve a drug homogeneity with relative standard deviation ≤5.0% at a 95% confidence interval across thief-probe samples. Light mineral oil is added at 0.5–1.0% w/w as a dust suppressant only after the active has been fully dispersed; oil levels above 1.0% cause carrier agglomeration and reduce flow through metering screws. Residual peroxide in the carrier is limited to ≤10 mEq/kg because peroxides accelerate erythromycin N-oxide formation during storage. The premix is filled into 25 kg multiwall paper bags with a 1-mil polyethylene inner liner and stored at ≤25°C and ≤60% relative humidity. Compliance for the finished medicated feed is assessed under FDA 21 CFR Part 225 for current good manufacturing practice and 21 CFR Part 558 for medicated feed applications; in the European Union, the relevant framework includes Regulation (EC) No 1831/2003 on feed additives and Commission Regulation (EU) No 37/2010 for residue limits, but authorizations are product-specific and the API alone does not establish legal dose or withdrawal period. Feed producers must verify cross-contamination control after each medicated run by a validated cleaning procedure because erythromycin is active at subtherapeutic carryover levels in non-target species. The terminal product is a dry medicated premix or feed granule for integration into complete poultry rations, not a directly administered oral solution.